This way, the PD-L1 target in gastric cancer could only be clinically effective (also in NAD-CT) for the subgroup of tumors that contain tumor-infiltrating immune cells and could explain the controversial results in the predictive effects of PD-L1 in response to PD-1/PD-L1 antibodies in GC [32]. This evidence concerns the gene CD274 and neoplasm.